To purchase hard copies of this book, please email:
orders@intechopen.com
By only printing on demand InTech ensures our carbon footprint is kept to a minimum.
The data below shows the environmental impact of printing one single book:
64.65 kg wood
3.48 g CO2
58.7 ml Water
Share this page
Chronic Lymphocytic Leukemia
Edited by Pablo Oppezzo, ISBN 978-953-307-881-6, Hard cover, 448 pages, Publisher: InTech, Published: February 10, 2012 under CC BY 3.0 license, in subject Oncology
DOI: 10.5772/1156
B-cell chronic lymphocytic leukemia (CLL) is considered a single disease with extremely variable course, and survival rates ranging from months to decades. It is clear that clinical heterogeneity reflects biologic diversity with at least two major subtypes in terms of cellular proliferation, clinical aggressiveness and prognosis. As CLL progresses, abnormal hematopoiesis results in pancitopenia and decreased immunoglobulin production, followed by nonspecific symptoms such as fatigue or malaise. A cure is usually not possible, and delayed treatment (until symptoms develop) is aimed at lengthening life and decreasing symptoms. Researchers are playing a lead role in investigating CLL's cause and the role of genetics in the pathogenesis of this disorder. Research programs are dedicated towards understanding the basic mechanisms underlying CLL with the hope of improving treatment options.
This book is indexed in:
Book contents
- Chapter 1Selected Topics in Chronic Lymphocytic Leukemia Pathogenesis
- Chapter 2Microenvironment Interactions in Chronic Lymphocytic Leukemia: A Delicate Equilibrium Linking the Quiescent and the Proliferative Pool
- Chapter 3Dysregulation of Apoptosis and Proliferation in CLL Cells
- Chapter 4DNA Damage Response/Signaling and Genome (In)Stability as the New Reliable Biological Parameters Defining Clinical Feature of CLL
- Chapter 5Current Knowledge of Microarray Analysis for Gene Expression Profiling in Chronic Lymphocytic Leukemia
- Chapter 6Contribution of microRNAs to CLL Biology and Their Potential as New Biomarkers
- Chapter 7The Biological Relevance of ZAP-70 in CLL
- Chapter 8Pathophysiology of Protein Kinase C Isozymes in Chronic Lymphocytic Leukaemia
- Chapter 9The Role of Polymorphisms in Co-Signalling Molecules’ Genes in Susceptibility to B-Cell Chronic Lymphocytic Leukaemia
- Chapter 10Mouse Models of Chronic Lymphocytic Leukemia
- Chapter 11Altering microRNA miR15a/16 Levels as Potential Therapy in CLL: Extrapolating from the De Novo NZB Mouse Model
- Chapter 12Prognostic Factors in Chronic Lymphoid Leukemia and Identification of New Clinically Relevant Molecular Markers
- Chapter 13Genetics of Chronic Lymphocytic Leukemia: Practical Aspects and Prognostic Significance
- Chapter 14Immune Response and Immunotherapy in Chronic Lymphocytic Leukemia
- Chapter 15In Vitro Sensitivity Testing in the Assessment of Anti-CLL Drug Candidates
- Chapter 16Interactions of the Platinum(II) Complexes with Nitrogen- and Sulfur-Bonding Bio-Molecules in Chronic Lymphocytic Leukemia
- Chapter 17Infectious Diseases and Clinical Complications During Treatment in CLL
- Chapter 18Emerging Therapies in Chronic Lymphocytic Leukemia
- Chapter 19Heat Shock Proteins in Chronic Lymphocytic Leukaemia
- Chapter 20Present and Future Application of Nanoparticle Based Therapies in B-Chronic Lymphocytic Leukemia (B-CLL)
